SCHEMBL20119652

SCHEMBL20119652

O=C(O)c1ccc(CNc2nc(Cl)nc3[nH]ccc23)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 1/20 0.51
PDE5A O76074 2/20 0.46
APP P05067 1/20 0.46
CNR1 P21554 1/20 0.44
ALDH1A1 P00352 2/20 0.43
HDAC3 O15379 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC2 Q92769 1/20 0.43
HDAC10 Q969S8 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
YTHDC1 Q96MU7 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.40
CSNK2A1 P68400 2/20 0.40
POLB P06746 1/20 0.40
HPGD P15428 1/20 0.40
HSD17B10 Q99714 1/20 0.40
CTDSP1 Q9GZU7 1/20 0.40
CSNK2A2 P19784 1/20 0.40
CSNK2B P67870 1/20 0.40
PDE2A O00408 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20119651 0.81 APP (0.44) HDAC6PDE5AAPPCNR1HDAC3
SCHEMBL29833956 0.80 PDE5A (0.48) HDAC6PDE5AAPPL3MBTL1POLB
SCHEMBL20119397 0.80 PDE5A (0.48) HDAC6PDE5AAPPL3MBTL1POLB
SCHEMBL20119714 0.78 VNN1 (0.42) PDE5AAPPCNR1ALDH1A1YTHDC1
SCHEMBL7254764 0.78 CNR1 (0.57) PDE5AAPPCNR1ALDH1A1CTNNB1
SCHEMBL20119452 0.77 PDE5A (0.42) HDAC6PDE5AAPPHDAC3HDAC1
SCHEMBL20119986 0.74 APP (0.42) HDAC6PDE5AAPPALDH1A1PDE2A
SCHEMBL20119919 0.73 PKM (0.50) PDE5AAPPALDH1A1POLBHSD17B10
SCHEMBL7259510 0.73 HTT (0.59) PDE5AAPPALDH1A1HPGDKMT2A
SCHEMBL27840330 0.72 PDE5A (0.53) PDE5AAPPCNR1ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-20200283441-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2020-09-10 US disclosed
US-10676475-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2020-06-09 US disclosed
US-20180118748-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279007-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 HDAC6 2386/4885PDE5A 3202/4885APP 604/4885
US-10676475-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 HDAC6 2386/4885PDE5A 3202/4885APP 604/4885
US-20180118748-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 HDAC6 2386/4885PDE5A 3202/4885APP 604/4885
US-11702417-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 HDAC6 2386/4885PDE5A 3202/4885APP 604/4885
US-20200283441-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 HDAC6 2386/4885PDE5A 3202/4885APP 604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.